Use of convalescent plasma for COVID-19 in India: A review & practical guidelines.
Antibody-dependent enhancement
COVID-19
anti-SARS-CoV-2 antibodies
convalescent plasma
donor selection
neutralizing antibodies
passive immunization
Journal
The Indian journal of medical research
ISSN: 0971-5916
Titre abrégé: Indian J Med Res
Pays: India
ID NLM: 0374701
Informations de publication
Date de publication:
Historique:
entrez:
5
4
2021
pubmed:
6
4
2021
medline:
16
4
2021
Statut:
ppublish
Résumé
Convalescent plasma (CP) therapy is one of the promising therapies being tried for COVID-19 patients. This passive immunity mode involves separating preformed antibodies against SARS-CoV-2 from a recently recovered COVID-19 patient and infusing it into a patient with active disease or an exposed individual for prophylaxis. Its advantages include ease of production, rapid deployment, specificity against the target infectious agent, and scalability. In the current pandemic, it has been used on a large scale across the globe and also in India. However, unequivocal proof of efficacy and effectiveness in COVID-19 is still not available. Various CP therapy parameters such as donor selection, antibody quantification, timing of use, and dosing need to be considered before its use. The current review attempts to summarize the available evidence and provide recommendations for setting up CP protocols in clinical and research settings.
Identifiants
pubmed: 33818467
pii: IndianJMedRes_2021_153_1_64_308620
doi: 10.4103/ijmr.IJMR_3092_20
pmc: PMC8184072
doi:
Substances chimiques
Antibodies, Neutralizing
0
Antibodies, Viral
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
64-85Déclaration de conflit d'intérêts
None
Références
Asian J Transfus Sci. 2015 Apr;9(Suppl 1):S1-2
pubmed: 26097329
Nat Med. 2020 Jul;26(7):1033-1036
pubmed: 32398876
Nat Med. 2020 Aug;26(8):1200-1204
pubmed: 32555424
Nat Rev Microbiol. 2004 Sep;2(9):695-703
pubmed: 15372080
Transl Med Commun. 2020;5(1):17
pubmed: 33072871
Transfus Clin Biol. 2016 Feb;23(1):39-44
pubmed: 26775794
J Infect. 2017 Mar;74(3):302-309
pubmed: 27867062
Nat Biotechnol. 2020 Jun;38(6):655-658
pubmed: 32358594
Nature. 2020 Mar;579(7798):270-273
pubmed: 32015507
Infect Dis Ther. 2020 Dec;9(4):913-926
pubmed: 32951151
Mayo Clin Proc. 2020 Sep;95(9):1888-1897
pubmed: 32861333
Clin Infect Dis. 2020 Nov 19;71(16):2027-2034
pubmed: 32221519
Emerg Microbes Infect. 2020 Dec;9(1):382-385
pubmed: 32065055
Nature. 2020 Aug;584(7821):437-442
pubmed: 32555388
Cell Rep Med. 2020 Jun 23;1(3):100040
pubmed: 32835303
J Clin Invest. 2020 Jun 1;130(6):2757-2765
pubmed: 32254064
Vox Sang. 2020 Aug;115(6):485-487
pubmed: 32319102
J Clin Invest. 2020 Sep 1;130(9):4791-4797
pubmed: 32525844
Clin Infect Dis. 2011 Feb 15;52(4):447-56
pubmed: 21248066
Nat Med. 2020 Nov;26(11):1708-1713
pubmed: 32934372
Infez Med. 2020 Sep 1;28(3):357-366
pubmed: 32920571
Eur J Clin Microbiol Infect Dis. 2005 Jan;24(1):44-6
pubmed: 15616839
J Infect Dis. 2006 Mar 15;193(6):792-5
pubmed: 16479513
J Antimicrob Chemother. 2005 Nov;56(5):919-22
pubmed: 16183666
Front Mol Biosci. 2020 Jul 03;7:157
pubmed: 32719810
J Infect Dis. 2015 Jan 1;211(1):80-90
pubmed: 25030060
Microbes Infect. 2020 Mar;22(2):72-73
pubmed: 32092539
Lancet. 1979 Dec 8;2(8154):1216-7
pubmed: 92624
J Med Virol. 2020 Sep;92(9):1475-1483
pubmed: 32356910
Clin Infect Dis. 2020 Jul 28;71(15):778-785
pubmed: 32198501
Antimicrob Agents Chemother. 1994 Aug;38(8):1695-702
pubmed: 7985997
JAMA. 2020 Apr 28;323(16):1582-1589
pubmed: 32219428
Blood. 2020 Aug 6;136(6):759-762
pubmed: 32559767
Haematologica. 2020 Jul 23;105(12):2834-2840
pubmed: 33256382
J Infect Dis. 2020 Jun 16;222(1):38-43
pubmed: 32348485
Chest. 2020 Jul;158(1):e9-e13
pubmed: 32243945
N Engl J Med. 2016 Jan 7;374(1):33-42
pubmed: 26735992
J Korean Med Sci. 2020 Apr 13;35(14):e149
pubmed: 32281317
J Clin Microbiol. 2020 Nov 18;58(12):
pubmed: 32917729
Emerg Infect Dis. 2016 Sep;22(9):1554-61
pubmed: 27532807
Science. 2017 Nov 17;358(6365):929-932
pubmed: 29097492
J Med Virol. 2020 Oct;92(10):1890-1901
pubmed: 32293713
Am J Pathol. 2020 Aug;190(8):1680-1690
pubmed: 32473109
Proc Natl Acad Sci U S A. 2020 Apr 28;117(17):9490-9496
pubmed: 32253318
Autoimmun Rev. 2020 Jul;19(7):102554
pubmed: 32380316
EClinicalMedicine. 2020 Sep;26:100525
pubmed: 32923991
Antivir Ther. 2018;23(7):617-622
pubmed: 29923831
Vox Sang. 2021 Jan;116(1):18-35
pubmed: 32533868
J Clin Invest. 2020 Oct 1;130(10):5112-5114
pubmed: 32634126
Emerg Infect Dis. 2020 Jul;26(7):1478-1488
pubmed: 32267220
BMJ. 2020 Oct 22;371:m3939
pubmed: 33093056
JAMA. 2020 Aug 4;324(5):460-470
pubmed: 32492084
N Engl J Med. 2007 Oct 4;357(14):1450-1
pubmed: 17914053
CMAJ. 2020 Jul 6;192(27):E745-E755
pubmed: 32444482
Blood Transfus. 2016 Mar;14(2):152-7
pubmed: 26674811
N Engl J Med. 2021 Feb 18;384(7):619-629
pubmed: 33232588
Front Immunol. 2020 May 15;11:1049
pubmed: 32574261
Am J Pathol. 2020 Nov;190(11):2290-2303
pubmed: 32795424
Asian Pac J Allergy Immunol. 2020 Mar;38(1):1-9
pubmed: 32105090
N Engl J Med. 2021 Feb 18;384(7):610-618
pubmed: 33406353
N Engl J Med. 2016 Dec 8;375(23):2307-2309
pubmed: 27959686